After dividing the 157 CN-AML patients into two groups based on the median ATP1B1 expression level, ATP1B1high expressers showed significantly shorter overall survival (OS) (P = 0.0068, Figure 3A) and event-free survival (EFS) (P = 0.0039, Figure 3B). The gene discussed is ATP1B1; the disease is acute myeloid leukemia.